Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer

被引:95
|
作者
Szabova, Ludmila [1 ]
Yin, Chaoying [4 ]
Bupp, Sujata [1 ]
Guerin, Theresa M. [1 ]
Schlomer, Jerome J. [1 ]
Householder, Deborah B. [1 ]
Baran, Maureen L. [1 ]
Yi, Ming [2 ]
Song, Yurong [3 ,4 ]
Sun, Wenping [2 ]
McDunn, Jonathan E. [5 ]
Martin, Philip L. [1 ]
Van Dyke, Terry [1 ,3 ,4 ]
Difilippantonio, Simone [1 ]
机构
[1] NCI Federick, Ctr Adv Preclin Res, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[2] NCI Federick, Adv Biomed Comp Ctr, SAIC, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA
[3] NCI Frederick, Mouse Canc Genet Program, Frederick, MD USA
[4] Univ N Carolina, Dept Genet, Chapel Hill, NC USA
[5] Metabolon Inc, Durham, NC USA
关键词
MOUSE MODEL; CONDITIONAL INACTIVATION; FALLOPIAN-TUBE; PERITONEAL MESOTHELIOMA; PAPILLARY CARCINOMA; DISTANT METASTASES; MUTATIONS; INDUCTION; WOMEN; P130;
D O I
10.1158/0008-5472.CAN-11-3834
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The majority of human high-grade serous epithelial ovarian cancer (SEOC) is characterized by frequent mutations in p53 and alterations in the RB and FOXM1 pathways. A subset of human SEOC harbors a combination of germline and somatic mutations as well as epigenetic dysfunction for BRCA1/2. Using Cre-conditional alleles and intrabursal induction by Cre-expressing adenovirus in genetically engineered mice, we analyzed the roles of pathway perturbations in epithelial ovarian cancer initiation and progression. Inactivation of RB-mediated tumor suppression induced surface epithelial proliferation with progression to stage I carcinoma. Additional biallelic inactivation and/or missense p53 mutation in the presence or absence of Brca1/2 caused progression to stage IV disease. As in human SEOC, mice developed peritoneal carcinomatosis, ascites, and distant metastases. Unbiased gene expression and metabolomic profiling confirmed that Rb, p53, and Brca1/2-triple mutant tumors aligned with human SEOC, and not with other intraperitoneal cancers. Together, our findings provide a novel resource for evaluating disease etiology and biomarkers, therapeutic evaluation, and improved imaging strategies in epithelial ovarian cancer. Cancer Res; 72(16); 4141-53. (C) 2012 AACR.
引用
收藏
页码:4141 / 4153
页数:13
相关论文
共 50 条
  • [41] BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer
    Richau, Caroline Stahnke
    Scherer, Nicole de Miranda
    Matta, Bruna Palma
    de Armas, Elvismary Molina
    Moreira, Fabio Carvalho de Barros
    Bergmann, Anke
    Chaves, Claudia Bessa Pereira
    Boroni, Mariana
    dos Santos, Anna Claudia Evangelista
    Moreira, Miguel Angelo Martins
    CANCER MEDICINE, 2024, 13 (03):
  • [42] Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan
    Liede, A
    Malik, IA
    Aziz, Z
    de los Rios, P
    Kwan, E
    Narod, SA
    AMERICAN JOURNAL OF HUMAN GENETICS, 2002, 71 (03) : 595 - 606
  • [43] Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer
    Daniels, Molly S.
    Urbauer, Diana L.
    Stanley, Jennifer L.
    Johnson, Kristin G.
    Lu, Karen H.
    GENETICS IN MEDICINE, 2009, 11 (09) : 624 - 628
  • [44] Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2
    Berchuck, A
    Carney, M
    Lancaster, JM
    Marks, J
    Futreal, AP
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1998, 41 (01): : 157 - 166
  • [45] Analysis of BRCA1 and BRCA2 alternative splicing in predisposition to ovarian cancer
    Jasiak, Anna
    Koczkowska, Magdalena
    Stukan, Maciej
    Wydra, Dariusz
    Biernat, Wojciech
    Izycka-Swieszewska, Ewa
    Buczkowski, Kamil
    Eccles, Michael R.
    Walker, Logan
    Wasag, Bartosz
    Ratajska, Magdalena
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2023, 130
  • [46] Missense Polymorphisms in BRCA1 and BRCA2 and Risk of Breast and Ovarian Cancer
    Dombernowsky, Sarah Louise
    Weischer, Maren
    Freiberg, Jacob Johannes
    Bojesen, Stig Egil
    Tybjaerg-Hansen, Anne
    Nordestgaard, Borge Gronne
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2009, 18 (08) : 2339 - 2342
  • [47] Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2
    Minion, L.
    Dolinsky, J.
    Chao, E.
    Monk, B.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 383 - 384
  • [48] Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2
    Minion, Lindsey E.
    Dolinsky, Jill S.
    Chase, Dana M.
    Dunlop, Charles L.
    Chao, Elizabeth C.
    Monk, Bradley J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 (01) : 86 - 92
  • [49] The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers
    Metcalfe, KA
    Lynch, HT
    Ghadirian, P
    Tung, N
    Olivotto, IA
    Foulkes, WD
    Warner, E
    Olopade, O
    Eisen, A
    Weber, B
    McLennan, J
    Sun, P
    Narod, SA
    GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 222 - 226
  • [50] Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer
    Choi, Min Chul
    Jang, Ja-Hyun
    Jung, Sang Geun
    Park, Hyun
    Joo, Won Duk
    Song, Seung Hun
    Lee, Chan
    Lee, Je Ho
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 (02) : 308 - 315